// App-Quantinova.ai

5012 : AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): Expanded analysis of the Johns Hopkins cohort.

Researchers

Presenter

  • Emmanuel S. Antonarakis

Principal Investigators

  • Changxue Lu

  • Brandon Luber

  • Hao Wang

  • Yan Chen

  • Yezi Zhu

  • John L. Silberstein

  • Maritza N. Taylor

  • Benjamin Louis Maughan

  • Channing Judith Paller

  • Samuel R. Denmeade

  • Kenneth J. Pienta

  • Michael Anthony Carducci

  • Mario A. Eisenberger

  • Jun Luo

Medical Centers

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD

  • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Androgen receptor variant 7

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • taxane

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved